Dementia research has reached a major milestone: Alzheimer’s disease is no longer considered to be untreatable, according to a landmark global report. The growing range of treatment options marks a shift from seeking a cure to focusing on avoiding the disease entirely.
Dementia research has entered an “era of unprecedented activity”, according to the 2026 World Alzheimer Report, co-authored by Alzheimer’s Disease International – a global federation affiliated with the World Health Organization – and health journalist Paul Gallagher.
After years of being considered an “inevitable consequence of old age and neurodegeneration”, Alzheimer’s is now seen as a condition for which “earlier diagnosis, better understanding of disease biology and a wider range of interventions may collectively improve outcomes”.
Hundreds of clinical trials are investigating “medicines, diagnostics, lifestyle interventions, digital technologies, rehabilitation programmes” and new care models for the disease, said the report.
During the past five years alone, novel drugs such as donanemab (brand name Kisunla) and lecanemab (brand name Leqembi) have been shown to “modestly slow decline in early Alzheimer’s”, said Science Alert.
The Alzheimer’s Association is “putting $100 million behind some research projects” to investigate existing medicines that may also be able to help treat the disease, particularly GLP-1s, said Vox. Years from now, when “millions of people are now on these GLP-1 drugs”, we may “start to see Alzheimer’s less often”. This would be “another reason to be optimistic” that the “future for this disease is looking brighter”.
|